Home Cart Sign in  
Chemical Structure| 2095432-65-6 Chemical Structure| 2095432-65-6

Structure of Verubecestat TFA
CAS No.: 2095432-65-6

Chemical Structure| 2095432-65-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Verubecestat is a potent and selective beta-secretase inhibitor and BACE1 protein inhibitor or Beta-site APP-cleaving enzyme 1 inhibitor with Kis of 2.2 and 0.38 nM for BACE1 and BACE2, respectively.

Synonyms: MK-8931 TFA; Verubecestat Trifluoroacetate; MK-8931

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Verubecestat TFA

CAS No. :2095432-65-6
Formula : C19H18F5N5O5S
M.W : 523.43
SMILES Code : O=C(NC1=CC=C(F)C([C@@](C2)(C)NC(N(C)S2(=O)=O)=N)=C1)C3=NC=C(F)C=C3.O=C(O)C(F)(F)F
Synonyms :
MK-8931 TFA; Verubecestat Trifluoroacetate; MK-8931
MDL No. :MFCD28963974
InChI Key :MNYVOIVLGITLBF-LMOVPXPDSA-N
Pubchem ID :129896720

Safety of Verubecestat TFA

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Verubecestat (MK-8931) TFA is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM, which effectively reduces Aβ40 and has the potential for Alzheimer's Disease[1].[2].

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse hippocampal CA1 slices 10 μM 5 h Verubecestat significantly inhibited long-term potentiation (LTP) in mouse hippocampal CA1 slices, reducing synaptic plasticity. PMC7687351

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice AppG-F and AppNL-G-F mice Oral 10 mg/kg Single dose, measured 3 hours after administration To evaluate the inhibitory effect of Verubecestat on Aβ levels. Results showed that Verubecestat significantly reduced Aβ40 and Aβ42 levels in the cortices of AppG-F mice, but not in AppNL-G-F mice. PMC9177067
Mice Tg2576-AβPP swe mice Dietary administration 110 mg/kg Continuous for 12 weeks To evaluate the effect of Verubecestat on microhemorrhage (ARIA-H) in aged Tg2576 mice, results showed that Verubecestat significantly suppressed the accumulation of brain Aβ40 and Aβ42 and did not significantly increase microhemorrhage events. PMC5611839

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02910739 Amnestic Mild Cognitive Impair... More >>ment|Alzheimer's Disease|Prodromal Alzheimer's Disease Less << PHASE1 COMPLETED 2017-04-12 -
NCT01537757 Alzheimer's Disease PHASE1 COMPLETED 2025-05-12 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.55mL

1.91mL

0.96mL

19.10mL

3.82mL

1.91mL

References

 

Historical Records

Categories